Patent application number | Description | Published |
20090268870 | Mobile radiation treatment vehicle and method - A mobile radiation treatment vehicle is disclosed including, a patient treatment compartment having at least one radiation shield member, the at least one radiation shield member positioned to prevent at least a portion of radiation emitted from a treatment device from passing through an interior of the patient treatment compartment to an outside area, the treatment device capable of emitting radiation used in connection with radiation therapy and positioned in the patient treatment compartment, and a shielded partition member positioned in the patient treatment compartment and proximate to the treatment device, the shielded partition member positioned to reduce or prevent exposure to a user from radiation emitted from the treatment device during patient treatment. | 10-29-2009 |
20120207276 | MOBILE RADIATION THERAPY - The invention provides techniques for diagnosing medical conditions and providing appropriate treatment at a patient's home residence. A mobile x-ray team can be dispatched to the patient's home residence. A technical team reviews patient data to determine a proper therapy plan. A mobile radiation therapy apparatus is dispatched to the patient's home as required by the therapy plan. The mobile radiation therapy apparatus includes a radiation source and shielding, and is capable of superficial radiation therapy and/or High Dose Rate (HDR), Low Dose Rate (LDR), and Medium Dose Rate (MDR) implant therapy and/or particle therapy. For HDR, LDR and MDR therapy, the mobile radiation therapy apparatus itself is a specialized radiation vault which the patient will enter. The technical team adjusts the therapy plan based on the additional analysis, and the mobile radiation therapy apparatus is dispatched in accordance with adjusted therapy plan. | 08-16-2012 |
Patent application number | Description | Published |
20090175414 | MOBILE RADIATION THERAPY - A mobile radiation therapy apparatus includes a vehicle cabin including driving controls for the vehicle cabin. A patient treatment compartment is rigidly attached to the vehicle cabin. A high dose rate radiation source configured to emit radiation is disposed within the patient treatment compartment. A patient treatment table is disposed within the patient treatment compartment and in proximity to the radiation source. A radiation shield is disposed around the patient treatment table, the radiation shield including a plurality of radiation shield sections rigidly attached to the patient treatment compartment and configured to substantially impede the radiation emitted from the radiation source. | 07-09-2009 |
20090252293 | Mobile radiation therapy - The invention provides techniques for diagnosing medical conditions and providing appropriate treatment at a patient's home residence. A mobile x-ray team can be dispatched to the patient's home residence. A technical team reviews patient data to determine a proper therapy plan. A mobile radiation therapy apparatus is dispatched to the patient's home as required by the therapy plan. The mobile radiation therapy apparatus includes a radiation source and shielding, and is capable of superficial radiation therapy and/or High Dose Rate (HDR) implant therapy. For HDR therapy, the mobile radiation therapy apparatus itself is a specialized radiation vault which the patient will enter. The technical team adjusts the therapy plan based on the additional analysis, and the mobile radiation therapy apparatus is dispatched in accordance with adjusted therapy plan. | 10-08-2009 |
20120069961 | MOBILE RADIATION THERAPY - The invention provides techniques for diagnosing medical conditions and providing appropriate treatment at a patient's home residence. A mobile x-ray team can be dispatched to the patient's home residence. A technical team reviews patient data to determine a proper therapy plan. A mobile radiation therapy apparatus is dispatched to the patient's home as required by the therapy plan. The mobile radiation therapy apparatus includes a radiation source and shielding, and is capable of superficial radiation therapy and/or High Dose Rate (HDR), Low Dose Rate (LDR), and Medium Dose Rate (MDR) implant therapy and/or particle thereapy. For HDR, LDR and MDR therapy, the mobile radiation therapy apparatus itself is a specialized radiation vault which the patient will enter. The technical team adjusts the therapy plan based on the additional analysis, and the mobile radiation therapy apparatus is dispatched in accordance with adjusted therapy plan. | 03-22-2012 |
20120112092 | Mobile radiation therapy - The invention provides techniques for diagnosing medical conditions and providing appropriate treatment at a patient's home residence. A mobile x-ray team can be dispatched to the patient's home residence. A technical team reviews patient data to determine a proper therapy plan. A mobile radiation therapy apparatus is dispatched to the patient's home as required by the therapy plan. The mobile radiation therapy apparatus includes a radiation source and shielding, and is capable of superficial radiation therapy and/or High Dose Rate (HDR), Low Dose Rate (LDR), and Medium Dose Rate (MDR) implant therapy and/or particle therapy. For HDR, LDR and MDR therapy, the mobile radiation therapy apparatus itself is a specialized radiation vault which the patient will enter. The technical team adjusts the therapy plan based on the additional analysis, and the mobile radiation therapy apparatus is dispatched in accordance with adjusted therapy plan. | 05-10-2012 |
Patent application number | Description | Published |
20110142760 | PSMA-BINDING AGENTS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis. | 06-16-2011 |
20120009121 | PSMA-TARGETING COMPOUNDS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described. | 01-12-2012 |
20140178300 | THERANOSTIC IMAGING AGENTS AND METHODS OF USE - The present invention provides targeted nanoplex molecules which carry multimodality imaging reporters together with target enzyme inhibitors such as siRNAs and target prodrug enzymes, that are useful for theranostic imaging of cells and diseases, including, for example, various cancers, and including metastatic prostate cancer. The nanoplex molecules of the present invention provide a platform technology toward many cancer subtypes and alternative therapeutic targets. Downregulation of specific pathways using targeted enzyme inhibitors further provides unique opportunities to target cancer cells selectively while sparing normal tissue. The nanoplex molecule platform described herein has the ability to deliver multiple siRNA enzyme inhibitors. Methods of diagnosis and treatment of various diseases are also included. The strategy described herein can be useful to down-regulate multi-drug resistance pathways, or repair enzymes with the goal of increasing the efficacy, safety, and efficiency of chemotherapeutic or irradiation therapies. | 06-26-2014 |
Patent application number | Description | Published |
20090010844 | Imaging Infection With Compounds That Bind to Thymidine Kinase - The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection. | 01-08-2009 |
20100034741 | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor - The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the α7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express α7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity. | 02-11-2010 |
20110176998 | IMAGING AND THERAPY OF VIRUS-ASSOCIATED TUMORS - The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection. | 07-21-2011 |
20110200677 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER - The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor. | 08-18-2011 |
20110212025 | TSPO-TARGETING COMPOUNDS AND USES THEREOF - Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described. | 09-01-2011 |
20130064767 | IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE - The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection. | 03-14-2013 |
20130164220 | COLLAGEN MIMETIC PEPTIDES FOR TARGETING COLLAGEN STRANDS FOR IN VITRO AND IN VIVO IMAGING AND THERAPEUTIC USE - The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Z | 06-27-2013 |
20140322133 | TSPO-TARGETING COMPOUNDS AND USES THEREOF - Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described. | 10-30-2014 |
20140369931 | PSMA-BINDING AGENTS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis. | 12-18-2014 |
Patent application number | Description | Published |
20090117042 | Imaging agents and methods of imaging NAALADase or PSMA - The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity. | 05-07-2009 |
20110064657 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), BIOLOGICAL EVALUATION, AND USE AS IMAGING AGENTS - The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors. | 03-17-2011 |
20110250129 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 - A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described. | 10-13-2011 |
20120276007 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA - The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity. | 11-01-2012 |
20130263296 | CANCER IMAGING WITH THERAPY: THERANOSTICS - Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided. | 10-03-2013 |
20140341804 | HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA) AND USES THEREOF - The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (α-, ε-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing. | 11-20-2014 |
20150044141 | SYNTHESIS AND APPLICATION OF NOVEL IMAGING AGENTS CONJUGATED TO DPA 713 ANALOGS FOR IMAGING INFLAMMATION - The present invention provides analog compounds of DPA-713 which specifically bind the translocator protein (TSPO), which is upregulated in activated leukocytes, some malignant tumors and tissues involved in steroid biogenesis. These compounds are linked via a linking moiety to a variety of imaging agents, including, for example, near infra-red dyes. The compounds of the present invention are useful for both pre-clinical near-IR fluorescence imaging (NIRF) and use in optically-guided interventions including NIRF endoscopy. Methods of use in diagnosis and treatment of TSPO related disease are also provided. | 02-12-2015 |
20150079001 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA - The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity. | 03-19-2015 |